Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in patients with hypertension and left ventricular hypertrophy? The LIFE study

被引：0
|
作者：
Ibsen, H
Olsen, MH
Wachtell, K
Borch-Johnsen, K
Lindholm, L
Dahlof, B
Snapinn, S
机构：
[1] Glostrup Cty Hosp, Glostrup, Denmark
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[3] Umea Univ, Umea, Sweden
[4] Univ Gothenburg, Gothenburg, Sweden
[5] Merck, W Point, PA USA
来源：
JOURNAL OF HYPERTENSION | 2003年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [41] Losartan has positive effects on lipid metabolism compared to atenolol in patients with hypertension and electrocardiographic left ventricular hypertrophy.: The LIFE study.
    Olsen, MH
    Wachtell, K
    Beevers, G
    Dahlöf, B
    Devereaux, R
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Julius, S
    Kjeldsen, S
    Lederballe-Pedersen, O
    Lindholm, L
    Nieminen, M
    Omvik, P
    Oparil, S
    Wedel, H
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 423A - 423A
  • [42] Correlates of pulse pressure reduction during antihypertensive treatment (Losartan or Atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    Gerdts, E
    Papademetriou, V
    Palmieri, V
    Boman, K
    Björnstad, H
    Wachtell, K
    Giles, TD
    Dahlöf, B
    Devereux, RB
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (04): : 399 - 402
  • [43] Effect of losartan compared to atenolol on cardiovascular mortality and morbidity in high and low risk patients with left ventricular hypertrophy.: A losartan intervention for endpoint reduction -: The LIFE study
    Franklin, SS
    Wachtell, K
    Papademetriou, V
    Olsen, MH
    Ibsen, H
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Dahlöf, B
    JOURNAL OF HYPERTENSION, 2003, 21 : S67 - S67
  • [44] The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Fossum, E
    Moan, A
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Snapinn, SM
    Edelman, JM
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristianson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Dahlöf, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) : 770 - 775
  • [45] Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy -: The LIFE (losartan intervention for endpoint reduction in hypertension) study
    de Simone, G
    Wachtell, K
    Palmieri, V
    Hille, DA
    Beevers, G
    Dahlöf, B
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Julius, S
    Kjeldsen, SE
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Devereux, RB
    CIRCULATION, 2005, 111 (15) : 1924 - 1931
  • [46] Long-term plasma catecholamines in patients with hypertension left ventricular hypertrophy treated with losartan or atenolol. Icarus, a LIFE substudy
    Fossum, E
    Olsen, MH
    Hoieggen, A
    Wachtell, K
    Reims, HM
    Ibsen, H
    Julius, S
    Kjeldsen, SE
    JOURNAL OF HYPERTENSION, 2004, 22 : S46 - S46
  • [47] Risk predictors for cardiovascular outcomes in patients with hypertension and left ventricular hypertrophy: The LIFE study
    Kjeldsen, SE
    Julius, S
    Snapinn, S
    Lyle, PA
    Devereux, RB
    Dahlof, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 424A - 424A
  • [48] An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Boersma, Cornelis
    Carides, George W.
    Atthobari, Jarir
    Voors, Adriaan A.
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2007, 29 (05) : 963 - 971
  • [49] Omapatrilat versus losartan in hypertensive patients with left ventricular hypertrophy
    Dahlof, B
    Agabiti-Rosei, E
    Zaliunas, R
    Moisejev, V
    Adamus, J
    Ruilope, L
    Keidar, S
    Levy, E
    JOURNAL OF HYPERTENSION, 2000, 18 : S42 - S42
  • [50] Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy -: A Losartan Intervention For Endpoint Reduction (LIFE) substudy
    Kjeldsen, SE
    Dahlöf, B
    Devereux, RB
    Julius, S
    Aurup, P
    Edelman, J
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristianson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Snapinn, S
    Wedel, H
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (12): : 1491 - 1498
12345